| Date | Title | Description |
| 27.03.2024 | Recbio And Rongsheng Biotech Signed a Strategic Cooperation Agreement On The New Adjuvant Vaccine Project | TAIZHOU, China, March 27, 2024 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (hereafter referred to as Recbio; stock code: 02179.HK) and Shanghai Rongsheng Biotech Co.,Ltd.(hereafter referred to as "Rongsheng Biotech") succe... |
| 21.03.2024 | Jiangsu Recbio Technology Co., Ltd. announced 2023 annual results report and latest progress | TAIZHOU, China, March 21, 2024 /PRNewswire/ -- Innovative vaccine company Recbio (02179.HK) announced its latest progress and annual results for 2023. The company always adhered to the mission of " Protect Human Health With Best-In-Cla... |
| 29.12.2023 | Positive Results In The Interim Analysis Of The Clinical Trial Of Recbio's Novel Adjuvanted Recombinant Shingles Vaccine REC610 In The Philippines | TAIZHOU, China, Dec. 29, 2023 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that the novel adjuvanted recombinant shingles vaccine... |
| 24.10.2023 | Recbio appeared at the 14th China (Taizhou) International Pharmaceutical Fair | TAIZHOU, China, Oct. 24, 2023 /PRNewswire/ -- From October 19 to 22, the 14th China (Taizhou) International Pharmaceutical Fair, sponsored by the China Chamber of International Commerce and hosted by the Taizhou Municipal People's Governmen... |
| 10.10.2023 | Recbio signed a strategic cooperation agreement with Zimbabwe National Biotechnology Administration and ICGEB China Regional Research Centre | TAIZHOU, China, Oct. 10, 2023 /PRNewswire/ -- On October 8, 2023, Dr. Deckster Tonny SAVADYE, CEO of Zimbabwe NBA, and Dr. Yang Yili, International Centre for Genetic Engineering and Biotechnology China Regional Research Centre(ICGEB), visi... |
| 28.08.2023 | Jiangsu Recbio Technology Co., Ltd. announced 2023 interim results report and latest progress | TAIZHOU, China, Aug. 28, 2023 /PRNewswire/ -- Innovative vaccine company Recbio (02179.HK) announced its latest progress and interim results for 2023. During the reporting period, the company always adhered to the mission of " Protect ... |
| 27.07.2023 | Acceptance Of Clinical Trial Application For The Recbio's Novel Adjuvanted Recombinant Shingles Vaccine REC610 In China And Overseas Clinical Trial Progress | TAIZHOU, China, July 27, 2023 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the"Board") is pleased to announce that the Group has recently received the notice of acceptance (acceptance number: CXSL2300518) issued by Nationa... |
| 17.05.2023 | Inclusion of Recbio In the MSCI China Small Cap Index | TAIZHOU, China, May 17, 2023 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that, MSCI announced the results of the semi-annual rev... |
| 21.03.2023 | Two-Component Recombinant COVID-19 Vaccine ReCOV Granted With Emergency Use Authorization In Mongolia | TAIZHOU, China, March 21, 2023 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that in accordance with the Mongolian law on the prev... |
| 13.02.2023 | Completion Of The First Batch Of Subject Enrollment For The Phase I Clinical Trial Of The Company's Novel Adjuvanted Recombinant Shingles Vaccine REC610 | TAIZHOU, China, Feb. 13, 2023 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that the Group has recently completed the first batch ... |
| 26.12.2022 | Superior Neutralizing Antibody Titer Levels Against Omicron BF.7 And BA.2.75 Of The Company's Two-Component Recombinant COVID-19 Vaccine ReCOV As Compared To International Mainstream mRNA Vaccine | TAIZHOU, China, Dec. 25, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that positive results were achieved for its sequential... |
| 26.12.2022 | Superior Neutralizing Antibody Titer Levels Against Omicron BF.7 And BA.2.75 Of The Company's Two-Component Recombinant COVID-19 Vaccine ReCOV As Compared To International Mainstream mRNA Vaccine | TAIZHOU, China, Dec. 26, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that positive results were achieved for its sequential... |
| 19.12.2022 | Clinical Trial Approval For The Company's Novel Adjuvanted Recombinant Shingles Vaccine REC610 In The Philippines | TAIZHOU, China, Dec. 19, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that, the Group has recently received the clinical tri... |
| 19.12.2022 | Clinical Trial Approval For The Company's Novel Adjuvanted Recombinant Shingles Vaccine REC610 In The Philippines | TAIZHOU, China, Dec. 19, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that, the Group has recently received the clinical tri... |
| 14.12.2022 | Superior Results Of The Comparative Study Of The Company's Recombinant Two-Component COVID-19 Vaccine ReCOV As Compared To International Mainstream mRNA Vaccine | TAIZHOU, China, Dec. 14, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that positive results were achieved for its sequential... |
| 21.11.2022 | Jiangsu Recbio Technology Co., Ltd. Increases Production For The First Phase Of Manufacturing Facility With A Maximum Annual Output Of 20 Million Doses Of Recombinant HPV 9-Valent Vaccine | TAIZHOU, China, Nov. 21, 2022 /PRNewswire/ -- (the "Company", together with its subsidiaries, the "Group") on voluntary basis. The board of directors of the Company (the "Board") is pleased to announce that in ... |
| 21.11.2022 | Jiangsu Recbio Technology Co., Ltd. Increases Production For The First Phase Of Manufacturing Facility With A Maximum Annual Output Of 20 Million Doses Of Recombinant HPV 9-Valent Vaccine | TAIZHOU, China, Nov. 21, 2022 /PRNewswire/ -- (the "Company", together with its subsidiaries, the "Group") on voluntary basis. The board of directors of the Company (the "Board") is pleased to announce that in ... |
| 08.11.2022 | Update on overseas clinical trials progress of novel adjuvant COVID-19 vaccine ReCOV | TAIZHOU, China, Nov. 8, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that positive results were achieved for its primary vac... |
| 28.10.2022 | Acceptance Of The Application For Clinical Trial Of Recbio Novel Adjuvanted Recombinant Quadrivalent HPV Vaccine | TAIZHOU, China, Oct. 28, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that, the Group has recently received a notice of acce... |
| 29.08.2022 | Recbio Announces Interim results for the Fiscal Year 2022 and Company Progress | The nine-valent HPV vaccine and other blockbuster varieties have been advanced efficiently.
Cash reserve was nearly RMB 1.5 billion, which provided support to sustainable innovation and commercialization.
The novel adjuvants vaccine will cr... |
| 19.08.2022 | Completion Of Subject Enrollment And Vaccination For The Comparative Study Between ReCOV And mRNA Vaccines | TAIZHOU, China, Aug. 19, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that, the Company has completed the subject enrollment... |
| 19.08.2022 | Completion Of Subject Enrollment And Vaccination For The Comparative Study Between ReCOV And mRNA Vaccines | TAIZHOU, China, Aug. 18, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that, the Company has completed the subject enrollment... |
| 10.08.2022 | Recbio announces Phase III Clinical Trial Progress Of Recombinant HPV 9-Valent Vaccine | TAIZHOU, China, Aug. 10, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the"Company", together with its subsidiaries, the "Group", Stock code: 02179.HK) is pleased to announce that, the Company has recently co... |
| 03.08.2022 | Approval Of The Comparative Study Between ReCOV And mRNA Vaccines By FDA In The Philippines | TAIZHOU, China, Aug. 3, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the"Company", together with its subsidiaries, the "Group",Stock code:02179.HK) is pleased to announce that, the Company has recently recei... |
| 27.06.2022 | Clinical Trial Approval For mRNA Covid-19 Vaccine For Omicron Variant In The Philippines | TAIZHOU, China, June 27, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. is pleased to announce that, the Group has recently received the clinical trial approval (the"Clinical Trial Approval") for its R520A, a mRNA COVID-... |
| 05.05.2022 | Clinical Trial Approval For ReCOV In The PRC And The Overseas Clinical Trial Progress Of ReCOV | TAIZHOU, China, May 5, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the"Company", together with its subsidiaries, the "Group",Stock code:2179.HK) is pleased to announce that the Company has recently received... |
| 13.04.2022 | Receipt Of Approval From The UAE For Phase II/III Clinical Trial Of Sequential Booster Vaccination For ReCOV | TAIZHOU, China, April 13, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the"Company", together with its subsidiaries, the "Group",Stock code:2179.HK) is pleased to announce that the Company has received appro... |
| 11.04.2022 | Successful Passing Of The EU Qualified Person Audit Of The Group's Manufacturing Facility For ReCOV In Taizhou | TAIZHOU, China, April 11, 2022 /PRNewswire/ -- The board of directors of Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group",Stock code:2179.HK) is pleased to announce that, on... |
| 21.03.2022 | Recbio Announces Proposed Listing on the Main Board of the Hong Kong Stock Exchange | Offer Price of HK $24.80 per H Share
To Raise Proceeds Up to HK$765 Million
Focus on the R&D of HPV Vaccine Candidates
Focus on In-house Research and Development of Novel Vaccines
TAIZHOU, China, March 21, 2022 /PRNewswire/ -- The China... |
| 15.02.2022 | Recbio Provides Updates on First Lyophilized mRNA Vaccine and Pre-clinical Data Showing Long-term stability and Strong immunogenicity against SARS-CoV-2 | TAIZHOU, China, Feb. 15, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (Recbio), a China-based company focused on the development of innovative vaccines for major diseases, announced preclinical data of its subsidiary Wuhan Recog... |
| 17.01.2022 | The Philippines Has Approved ReCOV For Phase II/III Cinical Trial | Recombinant Two-Component COVID-19 Vaccine (ReCOV) was approved for International Phase II/III Clinical Trial
ReCOV induced high levels of neutralizing antibodies against SARS-CoV-2 and Variants of Concern such as Omicron and Delta
Rhecogen... |
| 17.11.2021 | Recbio Receives Pharmaceutical Production License from Jiangsu Medical Products Administration for Production of COVID-19 Vaccine | TAIZHOU, China, Nov. 17, 2021 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. ("Recbio"), a biopharmaceutical company focusing on the research, development and commercialization of innovative vaccines that can address prevalen... |
| 12.11.2021 | Recbio Announces Promising Preliminary Results From First-in-Human Study of a COVID-19 Vaccine Candidate With Novel Adjuvant BFA03 | Well tolerated and good safety profile, no SAE or TEAE leading to early discontinuation, no abnormal vital signs/laboratory testing results with clinical significance
20μg ReCOV induced high titer of anti-SARS-CoV-2 neutralizing antibodies,... |
| 09.11.2021 | Recbio Announces New Study Showing Its COVID-19 Vaccine Induced High Levels of Neutralizing Antibodies against SARS-CoV-2 and Variants of Concern | TAIZHOU, China, Nov. 9, 2021 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. ("Recbio"), a biopharmaceutical company focusing on the research, development and commercialization of innovative vaccines that can address prevalent... |
| 29.09.2021 | Recbio and Rhegen Signed an mRNA Vaccine Cooperation Agreement | TAIZHOU, China, Sept. 29, 2021 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (referred to as "Recbio") and Shenzhen Rhegen Biotechnology Co., Ltd. (referred to as "Rhegen Bio") recently signed a joint venture agree... |
